Acquisition will bolster Sanofi's work on a U.S.-approved type 1 diabetes therapy and strengthen its drug pipeline following development setbacks.
Reuters reported French pharmaceutical company Sanofi SA has agreed to acquire Provention Bio Inc for $2.9 billion in cash to strengthen its drug pipeline following development setbacks.
The acquisition would give Sanofi full ownership of Tzield, a drug that was approved in the United States last year for delaying the onset of the third and final stage of type 1 diabetes. The deal builds on an existing co-promotion agreement between the two companies, and Sanofi expects to complete the acquisition in the second quarter of 2023.
While Sanofi's asthma and eczema drug Dupixent are boosting sales, its drug development pipeline has been criticised as weak by investors. Provention Bio's shares nearly quadrupled in premarket trade from their last close at $6.70 after the announcement.
Beyond the Scrubs: Understanding Healthcare Providers as People for Increased Engagement
March 28th 2024The benefits of adopting a humanized approach to healthcare provider marketing extend across the healthcare spectrum, enhancing engagement rates, brand loyalty, and marketing ROI, while also driving better outcomes for patients.
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.